Factors influencing mucosal healing in crohn's disease during infliximab treatment

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 1041-1046

  Tursi, Antonio ^a   Elisei, Walter ^b   Giorgetti, Gian Marco ^c   Penna, Antonio ^d   Picchio, Marcello ^e   Brandimarte, Giovanni ^f  

^a ASL BAT   (Italy)

^b ASL RMH   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d Division of Gastroenterology   (Italy)

^e Cristoforo Colombo Hospital   (Italy)

^f Cristo Re Hospital   (Italy)

Author keywords

Crohn's disease; Infliximab; Mucosal healing; Remission

Indexed keywords

AZATHIOPRINE; CHLORPHENIRAMINE; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COLITIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HOSPITAL PATIENT; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ULCER; MALE; MUCOSAL HEALING; PREDICTION; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT INDICATION; WOUND HEALING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84885807238     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11514     Document Type: Article

References (33)

1. Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009; 361:2066-2078.
2. Hecht GA: Inflammatory bowel disease - live transmission. N Engl J Med 2008; 358:528-530.
3. Danese S: Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008; 40(Suppl 2):S225-228.
4. Dignass A, Van Assche G, Lindsay JO et al.; European Crohn's and Colitis Organisation (ECCO): The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4:28-62.
5. Sandborn WJ: Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008; 135:1442-1447.
6. Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110:45-51. (Pubitemid 26021603)
7. Munkholm P, Langholz E, Davidsen M, Binder V: Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30:699-706,
8. Sandborn WJ, Feagan BG, Hanauer SB, et al.: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122:512-530. (Pubitemid 34117002)
9. Baert F, Moortgat L, Van Assche G et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468.
10. Winship DH, Summers RW, Singleton JW, et al.: National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979; 77(4 Pt 2):829-842. (Pubitemid 9257851)
11. Guyatt G, Mitchell A, Irvine EJ, et al.: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96:804-810. (Pubitemid 19057603)
12. Mary J Y, Modigliani R: Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30:983-989.
13. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007; 13:1024-1030. (Pubitemid 47309975)
14. Hanauer SB, Sandborn WJ, Dallaire C, et al.: Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21:827-834. (Pubitemid 351255702)
15. Hanauer SB, Sandborn WJ, Kornbluth A, et al.: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100:2478-2485.
16. Olaison G, Sjodahl R, Tagesson C: Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31:325-328. (Pubitemid 20093672)
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al.; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
18. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel J-F: Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7:15-29.
19. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413. (Pubitemid 38182297)
20. Colombel JF, Sandborn WJ, Reinisch W et al.; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395.
21. Freeman HJ: Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 2010; 16:15-20.
22. D'Haens G, Sandborn WJ, Feagan BG, et al.: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786.
23. Schnitzler F, Fidder H, Ferrante M, et al.: Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301.
24. Laharie D, Reffet A, Belleannée G, et al.: Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011; 33:714-721.
25. Di Sabatino A, Saarialho-Kere U, Buckley MG, et al.: Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. Eur J Gastroenterol Hepatol 2009; 21:1049-1055.
26. Di Sabatino A, Pender SL, Jackson CL, et al.: Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133:137-149. (Pubitemid 47031137)
27. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al.: Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30:523-529.
28. Rutgeerts P, D'Haens GR, Van Assche GA, et al.: Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the EXTEND Trial. Gastroenterology 2009; 136(Suppl 1):A-116.
29. Weisman MH, Moreland LW, Furst DE, et al.: Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25:1700-1721. (Pubitemid 36801943)
30. Tursi A, Papa A, Maiorano M: Onset of severe perianal disease in Crohn's disease under treatment with infliximab: Successful treatment with adalimumab and setons drainage. Inflamm Bowel Dis 2011; 17:676-678.
31. D'Haens GR, Panaccione R, Higgins PD, et al.: The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199-212.
32. Mantzaris GJ, Christidou A, Sfakianakis M, et al.: Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15:375-382.
33. Fidder HH, Hommes DW: Anti-TNF and Crohn's disease: when should we start? Curr Drug Targets 2010; 11:143-147.